K. John Morrow Jr.
Monoclonal antibodies hold great promise for cancer treatment, because they can act specifically against cancer cells, an advantage unavailable in any other therapy. However many difficulties must be overcome before this therapy can be applied generally.
One of the most substantial obstacles to the development of cancer immunotherapy with monoclonal antibodies is the fact that no cancer-specific antigens have been shown; the current dogma proposes "tumor-associated" antigens that may also be present in fetal tissue or other normal cellular elements (1). Two approaches to the lack of satisfactory antigenic sites have been attempted with B-cell malignancies. First, efforts have been
Morrow KJ. Monoclonal Antibodies in the Treatment of B-Cell Malignancies. Ann Intern Med. ;109:263–265. doi: 10.7326/0003-4819-109-4-263
Download citation file:
Published: Ann Intern Med. 1988;109(4):263-265.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use